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Abstract
The incidence of food hypersensitivity and food allergies is on the rise and new treatment approaches are needed. We
investigated whether N. sativa, one of its components, thymoquinone, or synthetic opioid receptor (OR)-agonists can
alleviate food allergy. Hence, ovalbumin (OVA) -sensitized BALB/c-mice were pre-treated either with a hexanic N. sativa seed
extract, thymoquinone, kappa- (U50’4889) or mu-OR-agonists (DAMGO) and subsequently challenged intra-gastrically with
OVA. All 4 treatments significantly decreased clinical scores of OVA-induced diarrhea. N. sativa seed extract, thymoquinone,
and U50’488 also decreased intestinal mast cell numbers and plasma mouse mast cell protease-1 (MMCP-1). DAMGO, in
contrast, had no effect on mast cell parameters but decreased IFNc, IL-4, IL-5, and IL-10 concentration after ex vivo re-
stimulation of mesenteric lymphocytes. The effects on allergy symptoms were reversible by OR-antagonist pre-treatment,
whereas most of the effects on immunological parameter were not. We demonstrate that N. sativa seed extract significantly
improves symptoms and immune parameters in murine OVA-induced allergic diarrhea; this effect is at least partially
mediated by thymoquinone. ORs may also be involved and could be a new target for intestinal allergy symptom alleviation.
N. sativa seed extract seems to be a promising candidate for nutritional interventions in humans with food allergy.
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Introduction
The last few decades have seen a constant increase in allergic
manifestations with a striking prevalence in Western Countries
[1,2]. In infants and children, food proteins are among the most
potent inducers of allergic reactions. Depending on the country,
the prevalence of diagnosed food allergies (double-blinded,
placebo-controlled, food challenge confirmed) in the general
population is between 2.4% and 4% [3–5] and it can increase
up to 6% in children under 3 years of age [6–8]. Sensitization to
food antigens often results in intestinal symptoms such as oral
allergy syndrome, vomiting and diarrhea [9]. However, allergic
reactions to food are not limited to symptoms in the gastrointes-
tinal tract but can involve other body sites such as the skin in
atopic eczema. Food allergies are often caused by different
allergens according to the age of the patient. The most prevalent
allergenic foods in infants and children are milk and egg [3]. Most
children have outgrown their food allergies when reaching school
age [10], but in some of them, symptoms persist and, moreover,
they often develop allergic symptoms against other types of food
such as peanut, nuts, fish, soybeans or cereals [3]. Food related
allergic reactions represent a significant burden for patients and
their families and cause considerable health care costs. In most of
these patients, avoidance of the allergen is the only efficient
treatment. This bares the risk of nutritional deficiencies, especially
in children and almost always results in impairment of quality of
life for the patients as well as their families. Therefore, alternative
treatments are needed. As one way to find solutions research
groups have conducted clinical trials with remedies from
complementary and alternative medicine [11] like Tylophora indica
in asthma [12], butterbur in allergic rhinitis [13] and St. John’s
wort in atopic dermatitis [14]. Another plant that has gained more
and more interest for potential medical use in recent years is Nigella
sativa (N. sativa). N. sativa, a member of the Ranonuculaceae family,
also known as black cumin or black caraway has been shown to be
rich in polyunsaturated fatty acids [15], phospholipids [16] and
contains a number of active ingredients like thymoquinone, hydro-
thymoquinone and nigellone [17,18]. N. sativa is used in the
Middle East as remedy for a number of different diseases [19,20].
Various biological effects have been linked to the use of N. sativa
and some of its active ingredients. In particular thymoquinone has
been reported to have anti–inflammatory [21–23] and anti-cancer
[24] properties and to alleviate allergic asthma [25–27].
Additionally, N. sativa and its component thymoquinone have
been linked to anticonvulsive effects and pain protection, possibly
through opioid receptor (OR) mediated mechanisms [28–30].
ORs belong to the G protein-coupled receptor superfamily.
According to their pharmacological activity they are defined into
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(DOR). They have first been described in the central nervous
system for their involvement in pain regulation but have now been
found to be widely expressed in peripheral tissues including the
gastrointestinal tract. Intestinal ORs are involved in regulation of
motility [31], intestinal secretion [32] and bowel transit time [33],
these are mechanisms also involved in development of intestinal
symptoms of food allergy. Recently, molecular and functional
investigations have revealed that all three OR-subtypes are also
expressed on immune cells, where they have been shown to
modulate cytokine and chemokine production as well as the
expression of their receptors [34].
In the present study we investigated the effect of oral hexanic N.
sativa seed extract in ovalbumin (OVA)-induced allergic diarrhea
in mice. In this well described food allergy model [35], OVA-
sensitized mice develop transient diarrhea with progressively
increasing severity following multiple OVA-challenges. Clinical
symptoms are accompanied by elevated plasma mouse mast cell
protease-1 (MMCP-1, a marker for mast cell degranulation),
mastocytosis in the jejunum, elevated plasma IgE, and Th2-type
intestinal responses. We demonstrated that N. sativa seed extract
significantly improves symptoms and immune related markers in
murine OVA-induced allergic diarrhea and that the effect is
partially mediated by thymoquinone involving ORs.
Results
N. sativa seed extract alleviates symptoms and
modulates immune markers in mice with OVA-induced
allergic diarrhea
N. sativa seed extract significantly attenuated the diarrhea
severity (clinical macroscopic scores) at the final OVA-challenge
(p,0.001, Figure 1A+B) as well as the sum of clinical scores from
consecutive challenges (p,0.001, data not shown) when compared
to non-treated OVA-challenged controls. The decrease in clinical
symptoms was accompanied by a decrease in plasma concentra-
tion of MMCP-1 (p=0.006, Figure 1C) and intestinal mast cell
numbers (p=0.005, Figure 1D) in mice supplemented with N.
sativa seed extract. Total IgE or OVA-specific IgE concentrations
were not significantly decreased. N. sativa seed extract administra-
tion did not cause any change in IL-4, IL-5, IL-10 or IFNc release
from mesenteric lymphocytes following ex vivo re-stimulation with
OVA (data not shown).
Thymoquinone, one of the active components of N.
sativa seeds, alleviates symptoms and decreases immune
markers in mice with OVA-induced allergic diarrhea
One of the most potent components of N. sativa, shown to
modulate immune reactions, is the quinolone, thymoquinone
[21,36]. To investigate if thymoquinone was involved in mediating
the positive effects of N. sativa, mice were treated intragastrically
with thymoquinone, in a concentration corresponding to the one
that had been given with N. sativa seed extract in previous
experiments (13 mg/kg BW). Thymoquinone treatment resulted in
a decrease of the sum of clinical scores (p=0.006, Figure 2A, two
pooled experiments) and the diarrhea severity at the final
challenge (p=0.001, data not shown). Treatment with thymoqui-
none also decreased plasma MMCP-1 concentration (p=0.01,
Figure 2B) and intestinal mast cell numbers (p,0.001, Figure 2C
and 2D–F). Similarly to what was shown with N. sativa,n o
significant changes in total plasma IgE and OVA-specific IgE were
observed and intragastric treatment of mice with thymoquinone
did not cause any modulation in IL-4, IL-5, IL- 10 or IFNc
secretion by mesenteric lymphocytes after ex vivo re-stimulation
with OVA.
Thymoquinone displaces OR-ligands in vitro
Thymoquinone has been suggested to activate ORs. To
investigate whether ORs play a role mediating the positive effects
of thymoquinone and N. sativa in OVA-induced allergic diarrhea,
we first tested possible interactions of thymoquinone with ORs in
vitro. At a concentration of 100 mM thymoquinone showed
displacement of specific OR-ligands from their receptors in a
radio-ligand displacement assay. 45% of [
3H]DAMGO were
displaced from MOR, 35% of [
3H]U-69,593 from KOR, and
48% of [
3H]DADLE from DOR, indicating possible binding and
subsequent signalling of thymoquinone through OR (Table 1).
ORs are involved in mediating the positive effect of
thymoquinone and N. sativa
We next investigated the effect of OR-antagonist pre-treatment
on thymoquinone induced alleviation of allergic diarrhea in mice.
Subcutaneous pre-treatment of mice with the peripheral OR-
antagonist, naloxone-methiodide (30 mg/kg BW), strongly re-
duced the positive effect of thymoquinone on the sum of clinical
scores in OVA-allergic mice (p=0.01, Figure 2A) as well as the
thymoquinone-induced decrease in plasma MMCP-1 (p=0.02,
Figure 2B) and intestinal mast cell numbers (p=0.001,
Figure 2C and 2G).
Pre-treatment with 10 mg/kg BW of naloxone-methiodide also
reversed the protective effect of N. sativa seed extract (Figure 1A)
whereas, surprisingly, 30 mg/kg did not (Figure 1B). Pre-
treatment with Naloxone-methiodide did not have any impact
on N. sativa mediated decrease of MMCP-1 and intestinal
mastocytosis (Figure 1C+D). Naloxone-methiodide alone showed
no effect at 10 mg/kg BW and a mild effect when given at 30 mg/
kg BW when compared to positive control groups (Figures 1A
and 1B).
MOR- and KOR are involved in allergic diarrhea
Since the role of ORs in OVA-induced allergic diarrhea of mice
has not been demonstrated previously, we next assessed the
influence of OR activation on clinical symptoms and immune
parameters, using known OR-agonists. Involvement of DOR,
MOR and KOR was tested using the chemical agonists SNC80
and DPDPE, DAMGO, and U50’488, respectively. No measur-
able effect was observed using the DOR-agonist but pre-treating
mice by subcutaneous injection with the KOR-agonist U50’488 at
a concentration of 5 mg/kg BW, resulted in a significant,
reproducible decrease of the sum of clinical scores (p,0.001),
due to continuously lower scores from the 3
rd challenge onwards
(Figure 3A), and a low clinical macroscopic diarrhea scores at the
last challenge (p=0.005, data not shown). The beneficial effect of
U50’488 was strongly reduced in mice pre-treated with the
subcutaneous KOR-specific antagonist NorBNI (Figure 3A).
Administration of NorBNI alone had no effect on diarrhea scores
(Figure 3A). In order to investigate whether the effect seen with
the KOR-agonist U50’488 was purely anti-diarrheic, mice were
treated with U50’488 only at the time of diarrhea induction (for
two days before the 6
th challenge). This short term treatment failed
to protect mice from OVA-induced diarrhea.
As with U50’488, subcutaneous injection with the MOR-
agonist DAMGO at a concentration of 5 mg/kg BW, resulted in a
significant decrease in the sum of clinical scores (p=0.038) due to
decreased scores from the 3
rd challenge onwards (Figure 3B).
Subcutaneous injection of OR-antagonist naloxone-methiodide at
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preferably inhibit MOR) one hour before the administration of
DAMGO further attenuated the diarrhea scores, whereas
administration of naloxone-methiodide alone showed no effect
(Figure 3B).
MOR- and KOR-agonists differ in their effect on allergy
related immune parameters
KOR-agonist U50’488 decreased the plasma level of MMCP-1
(p=0.01, Figure 4A) and total plasma IgE (p=0.043, Figure S1).
Contrary to the results for clinical symptoms NorBNI pre-
treatment did not reverse the effect on MMCP-1 (Figure 4A)
and only partially reversed the effect on plasma IgE (Figure S1).
U50’488 showed no significant effect on cytokine release from
mesenteric lymphocytes after ex vivo stimulation with OVA (data
not shown). We next investigated the effect of DAMGO on
allergy-related immune parameters. DAMGO had no effect on
MMCP-1 and total plasma IgE (data not shown) but decreased the
concentration of IL-4 (p=0.02, Figure 4B), IFNc (p=0.02,
Figure 4C), IL-5 (p=0.02, Figure S2A), and IL-10 (p=0.04,
Figure S2B) after ex vivo re-stimulation of mesenteric lymphocytes
with OVA. The concentrations of these cytokines were further
decreased when mice were pre-treated with naloxone-methiodide
whereas naloxone-methiodide alone had no significant effect on
cytokine release (Figure 4B–C and Figure S2).
Discussion
Here we demonstrate that a hexanic extract of N. sativa seeds
decreases diarrhea scores and allergy related immune markers in
mice with OVA-induced allergic diarrhea. Recent results from the
literature indicate beneficial effects of N. sativa in respiratory
allergies [25,26]. Detailed studies conducted in in vivo allergy
models showed a decrease in blood eosinophils, total IgG1, total
IgG2 and lung inflammatory cells in mice with allergic asthma
[37]. Consistent with these effects, we show that N. sativa seed
extract also reliably decreased symptoms of food allergy reducing
the overall severity of OVA-induced diarrhea in OVA-allergic
mice. This effect of N. sativa was confirmed in four independent
experiments, using two different batches of hexanic N. sativa seed
extract. The reduction of symptoms is accompanied by a
decreased number of OVA-induced intestinal mucosal mast cells
and a reduction of OVA-induced plasma MMCP-1 increase. In
this mouse model, mast cells have been described as the main
mediators of symptoms, which has led to it being considered as a
model of local intestinal anaphylaxis [35]. It has been shown that
diarrhea is prevented when mast cells were depleted by
Figure 1. N. sativa seed extract decreases clinical macroscopic scores and immune parameters in OVA-allergic mice. OVA-sensitized
mice were challenged with saline (Saline), OVA (OVA), or with OVA after intragastric administration of N. sativa seed extract (Ns) with the OR
antagonist naloxone-methiodide pre-treatment at the dose indicated (Ns N-M), or with naloxone-methiodide alone (N-M). Panels A and B represent
the median of clinical macroscopic scores at sacrifice. Panels C and D show the plasma concentration of MMCP-1 (C) and the numbers of mast cells
per intestinal villus (D) at sacrifice. Each dot represents the corresponding value for one animal and the bars represent the median with interquartile
range, *=p,0.05; n=5–19.
doi:10.1371/journal.pone.0039841.g001
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mediators (platelet activating factor and serotonin) was inhibited
[35]. Mast cell stabilization and/or decrease in mast cell numbers
could therefore be involved in mediating the beneficial effect of N.
sativa seed extract. Previous data from the literature, regarding N.
sativa effect on mast cells, substantiate this hypothesis. In vitro
experiments in rat peritoneal mast cells, pre-treated with nigellone,
a carbonyl polymer of thymoquinone (one of the active
compounds in N. sativa) demonstrated an inhibition of histamine
release in response to antigen-specific activation [38]. Further-
more, Kanter and colleagues have reported that protection from
gastric ulcers with N. sativa treatment in rats was mediated by a
decrease in gastric mast cell numbers [39].
In the attempt to also test the influence of N. sativa on the
adaptive immune response, we re-stimulated murine mesenteric
lymph node (MLN) lymphocytes ex vivo with OVA to measure
cytokine release. Consistent with previously published results [40],
cells of N. sativa treated mice failed to demonstrate changes in
cytokine release. Together these changes suggest that local effector
mechanisms rather than changes in sensitization mediate the
beneficial effect of N. sativa in OVA-allergic mice.
The quinolone, thymoquinone, one of the lipophilic compounds
in hexanic extract from N. sativa seeds, has been shown to mediate
anti-cancer [41], anti-inflammatory [22], and anti-allergic [36]
benefits of N. sativa in animal models. We have demonstrated with
oral administration of thymoquinone to OVA-allergic mice that,
similar to the results with N. sativa seed extract, thymoquinone
provokes a decrease in symptoms, plasma MMCP-1 levels and
mast cell numbers in OVA-induced diarrhea. Contrary to
Figure 2. Thymoquinone decreases clinical symptoms, plasma MMCP-1 levels, and mast cell numbers in OVA-allergic mice. OVA-
sensitized mice were challenged with saline (Saline), OVA (OVA), or with OVA after intragastric treatment with 13 mg/kgBW thymoquinone (Thq) and
with thymoquinone after 30 mg/kgBW naloxone-methiodide pre-treatment (Thq N-M). Panel A represent the median of clinical macroscopic scores
at sacrifice. Panel B shows the plasma concentrations of MMCP-1 and Panel C the numbers of mast cells per intestinal villus at sacrifice. The dots
correspond to results from individual animals and the bars represent the median with interquartile range, *=p,0.05, panels show the results from
two pooled experiments, n=10–20. Panel D–G are representative histological pictures of mast cells in the jejunum of OVA-sensitized mice
challenged with saline (D), OVA (E), or with OVA after intragastric treatment with 13 mg/kgBW thymoquinone (F) and with thymoquinone after
30 mg/kgBW naloxone-methiodide pre-treatment (G). Mast cells appear in bright red.
doi:10.1371/journal.pone.0039841.g002
Table 1. In vitro ligand displacement by thymoquinone.
Opioid
receptor






a)20–50%=moderate displacement (Abbr.: MOR=m-opioid receptor, KOR=e ˆ-
opioid receptor, DOR=d-opioid receptor).
doi:10.1371/journal.pone.0039841.t001
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changes in total or OVA-specific IgE after thymoquinone
treatment. This discrepancy can most likely be linked to the route
of administration (intraperitoneal versus oral). Interestingly, a
milk-based extraction of N. sativa seeds, containing no thymoqui-
none, had no effect on allergic diarrhea (data not shown).
Together these results suggest that thymoquinone could be a
major active component mediating the beneficial effect of N. sativa
seed extract in OVA-induced allergic diarrhea.
Various mechanisms of action have been suggested for
thymoquinone such as inhibition of the cyclooxygenase and 5-
lipoxidase pathways [42], and regulation of the toll-like receptor
4/NF e ˆB pathway [43]. It has also been reported that oral
thymoquinone as well as N. sativa have an analgesic effect in
protection from peripheral pain in mice through an OR-mediated
mechanism [28]. OR-activation has recently also been reported to
have anti-inflammatory properties [44]. We were able to show that
thymoquinone displaces OR-agonists in vitro suggesting a possible
implication of OR-pathways in N. sativa and thymoquinone effects.
To our knowledge the effects of ORs in food allergy have not been
investigated in vivo. Thus, we first tested the functional effect of
OR-agonists in our mouse model. MOR and KOR are the two
ORs that are most widely expressed in the gut, whereas DOR is
less abundant. Treatment with either DAMGO (MOR-agonist) or
U50’488 (KOR-agonist) significantly improved the severity of
OVA-induced allergic diarrhea whereas DOR-agonist showed
inconclusive results (data not shown). Peripheral OR-agonists have
been demonstrated in the past to delay intestinal transit time and
decrease intestinal secretion through neurogenic mechanisms
resulting in a beneficial effect on diarrhea [32,33]. Interestingly,
KOR-agonist treatment did not only decrease diarrhea – OR-
agonist have long history as anti-diarrhoeic drugs [45,46] – but
also mast cell numbers and plasma MMCP-1 concentration in
OVA-allergic mice. This suggests an effect that involves the
mucosal immune response. Immune cells, specifically mucosal
mast cells have been shown to be in close proximity to neurons
[47] in the intestine and they functionally interact [48,49]. OR
could be involved in this interaction since Ussing chamber
experiments with intestine from beta–lactoglobulin sensitized pigs,
revealed that beta–lactoglobulin specific, mast cell induced,
neurogenic increase of intestinal secretion is alleviated by OR-
agonist treatment [48]. However, future experiments are required
to determine the mechanism of the KOR effect. It is noteworthy
that KOR-agonist did not show an effect on allergic diarrhea in
our mouse model when administered for only two days before the
final challenge, reinforcing the suggestion that the benefit of KOR
activation in allergic diarrhea goes beyond an anti-diarrheic effect
and that a more extended agonist treatment is required to show an
effect.
Contrary to KOR-agonist treatment, injection with MOR-
agonist DAMGO influenced neither serum MMCP-1 concentra-
tion nor mast cell numbers. In line with previous work on MORs
[50], which revealed an influence on immune mediator release
from inflammatory cells, we observed a significant decrease of
cytokines secreted from ex vivo OVA-stimulated mesenteric
lymphocytes in DAMGO-treated mice. The fact that U50’488
and DAMGO show different immune modulating capacities
suggests different mechanisms of action in murine allergic diarrhea
but may also result from differences in the expression pattern of
KOR and MOR on allergy-related immune cells.
In the experiments with DAMGO we used low dose (1 mg/kg
BW) naloxone-methiodide as MOR antagonist, according to its
high affinity to MOR. Paradoxically, treatment with low dose
DAMGO enhanced the beneficial effect on allergic diarrhea. It
has been reported in the literature that MOR-expression on the
cell surface is highly regulated and influenced by long term agonist
treatment, which can lead to OR-tolerance and opioid depen-
dence. For recycling of functionality following activation, MORs
need to be internalized, remodelled, and re-expressed on the
surface. Thus one of the mechanisms of agonist tolerance is
inactivation of cell surface ORs by circumvention of internaliza-
tion [51]. On the contrary, low dose, long term antagonist
treatment (as used in our model) has been shown to enhance
internalization of MOR, resulting in recycling and functional re-
expression of the receptor on the cell surface [52]. Combination of
high dose agonist and low dose antagonist (like done in our study)
could hence, paradoxically increase the total DAMGO signalling
through increased availability of functional MOR on the cell
surface (functional supersensitivity) and consequently result in an
increase of the beneficial effect. This has been reported for low
dose OR-antagonist treatment by others [52]. It also needs to be
considered that endogenous opioid receptor agonists, like beta-
endorphin, could be involved in the regulation of MOR expression
and might influence the effect of exogenous MOR agonist [53].
Further investigations measuring the expression of MOR and
binding studies using selective MOR-antagonists are needed to
fully explain these observations.
When testing the involvement of OR in the beneficial effect of
thymoquinone and N. sativa, antagonist pre-treatment inhibited
the effect of thymoquinone and N. sativa on diarrhea, mast cell
numbers, and plasma MMCP-1 concentration. We hence
conclude that the beneficial effect of N. sativa seed extract in
allergic diarrhea involves OR-signalling, most possibly through
thymoquinone. N. sativa seed extract, however, contains other
active compounds and we can hence not exclude that non-OR-
related pathways are involved. Especially, when keeping in mind
that the beneficial effect of N. sativa was inhibited by antagonist
pre-treatment with moderate dose (10 mg/kg BW) but, contrary to
thymoquinone, pre-treatment with high dose of 30 mg/kg BW
was not effective. Additional work is required to fully understand
the underlying mechanisms.
In conclusion, we have shown for the first time, that MOR- and
KOR-signalling are involved in murine allergic diarrhea and that
treatment with their respective agonists can decrease symptoms by
mechanisms that are going beyond a purely anti-diarrheic effect
and that involve modulation of immune parameters associated
with food allergy. Furthermore, we were able to show that this
pathway might have a clinical application by using an extract from
N. sativa seeds, which alleviates symptoms of allergic diarrhea and
modulates immune parameters in mice. The beneficial effect of N.
sativa extract seems to be at least partially mediated by its active
ingredient thymoquinone and involves OR-signalling. N. sativa
Figure 3. KOR-agonist (U50’488) and MOR-agonist (DAMGO) decrease symptoms in OVA-allergic mice. OVA-sensitized mice were
challenged with saline (Saline) or OVA (OVA) with or without pre-treatment. Panel A shows the sum of clinical symptoms after subcutaneous
treatment with 5 mg/kgBW KOR-agonist U50’488 (U50’488) and 20 mg/kgBW NorBNI (U50’488+NorBNI), or with NorBNI alone (NorBNI). Panel B
shows the sum of clinical symptoms after subcutaneous treatment with 5 mg/kgBW MOR-agonist (DAMGO) and naloxone-methiodide (DAMGO+N-M
1 mg), or naloxone-methiodide alone (N-M 1 mg). Each dot represents the corresponding value for one animal and the bars represent the median
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39841Figure 4. KOR-agonist (U50’488) and MOR-agonist (DAMGO) alleviate allergy related immune markers in OVA-allergic mice. OVA-
sensitized mice were challenged with saline (Saline) or OVA (OVA) with or without pre-treatment. The graph shows the concentration of total plasma
MMCP-1 (A) at sacrifice after subcutaneous treatment with 5 mg/kgBW KOR-agonist U50’488 (U50’488), with 20 mg/kgBW NorBNI (U50’488+NorBNI),
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interventions in humans suffering from food allergy.
Materials and Methods
Ethics statement
All experiments were approved by the District Veterinary Office
of the Canton Vaud, Lausanne, Switzerland and all procedures
conducted according to the Swiss Animal Protection Law
(Authorization # 1822 VD).
Animals
Male BALB/c mice (Charles River Breeding Laboratories,
France) were housed in groups of 5 animals in micro-isolator cages
in the Central Animal Facilities at the Nestle ´ Research Centre,
Lausanne, Switzerland. The cages were equipped with filter hoods
and kept under controlled temperature (20uC) with a 12:12 h
light-dark cycle and free access to food and water. The animals
were given one week after arrival at the animal facility to adapt to
the new environment and minimize stress. Afterwards they were
randomized by weight into the different experimental groups.
Sensitization and challenges (OVA-induced allergic
diarrhea)
Sensitization and challenge procedures were conducted as
previously published [35]. Briefly, the mice (6 weeks old) received
two intra-peritoneal injections with 50 mg chicken OVA (Sigma-
Aldrich, Germany) and 1 mg aluminium potassium sulphate
adjuvant (Alum) (Sigma-Aldrich, Germany) at intervals of two
weeks (Figure 5). Tail vein blood samples were tested for OVA-
specific IgE one week after the second i.p. injection to assess
sensitization levels. Thirteen days after the second sensitization the
mice were challenged with 50 mg OVA by intra-gastric gavage,
placed in individual cages and monitored for diarrhea symptoms
during one hour. The mice were scored according to feces
appearance as follows: score 0=no changes; score 1=soft but well
formed; score 2=soft, non-formed; score 3=one episode of liquid
diarrhea; score 4=at least two episodes of liquid diarrhea; score 5
(only at sacrifice)=score 4 and only clear liquid in the colon at
sacrifice. One hour after the 6
th challenge mice were sacrificed by
exsanguination under inhalation anaesthesia (isoflurane) and
blood, MLN, and intestinal tissue were taken for further analysis.
Hexanic extraction of N. sativa seeds
500 g of N. sativa seeds (Mehran Spice & Food Industries,
Pakistan) were ground using a laboratory mill. The ground seeds
were placed in a flask equipped with an overhead stirrer Heidolph
2041 (Heidolph Instruments GmbH & Co KG, Germany). The oil
was extracted twice for 1 hour using hexane (262500 ml). The
mixture was filtered and the solvent was removed using a rotatory
evaporator. The oil was recovered and stored at 220uC until use.
Treatments
N. sativa seed hexanic extract and thymoquinone (Sigma-
Aldrich, Germany) were given by intra-gastric gavage once a
day for 4 days starting 3 days before the two intraperitoneal
sensitizations. Treatment was started again 3 days before the first
challenge and continued daily until sacrifice (Figure 5). The
DOR-agonist 4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl](3-
methoxyphenyl)methyl]-N, N-diethylbenzamide (SNC80) or [D-
Pen2,5]-Enkephalin (DPDPE), the MOR-agonist [D-Ala
2,N -
MePhe
4, Gly-ol]-enkephalin (DAMGO), and the KOR-agonist 2-
(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclo-
hexyl]acetamide (U50’488) (all agonists from Sigma-Aldrich,
Germany) were injected subcutaneously at a concentration of
5 mg/kg BW once a day. When indicated, mice were injected
subcutaneously with the peripheral OR-antagonist naloxone–
methiodide (N-M) (concentration of 1 mg/kg, 10 mg/kg or
30 mg/kg) or the KOR-antagonist Norbinaltorphimine (NorBNI)
(concentration 20 mg/kg) (both Sigma-Aldrich, Germany) 1 h
prior to the agonist treatment. All subcutaneous administered
substances were dissolved in sterile saline. Due to the long lasting
antagonist effect of NorBNI the injection was given every other
day.
In vitro OR-binding assay
Interaction of thymoquinone with OR was tested in vitro for
MOR, KOR and DOR at CEREP (Le Bois l’Eve ˆque, BP 1, 88660
Celle l’Evescault) using previously published radiolabel-binding
assays [54–56] with the conditions displayed in Table 2. In each
or with NorBNI alone (NorBNI), and the concentration of plasma IL-4 (B) and IFN-gamma (C) after subcutaneous treatment with 5 mg/kgBW MOR-
agonist (DAMGO) and naloxone-methiodide (DAMGO+N-M 1 mg), or naloxone-methiodide alone (N-M 1 mg). MMCP-1 levels were unchanged with
MOR-agonist and IL-4 and IFN-gamma levels were unchanged with KOR-agonist respectively (data not shown). Each dot represents the
corresponding value for one animal and the bars represent the median and interquartile range, * p,0.05; n=5–10.
doi:10.1371/journal.pone.0039841.g004
Figure 5. Experimental set up for OVA-induced allergic diarrhea. Intervention corresponds to either intragastric N. sativa or thymoquinone
(with or without sub-cutaneous OR-antagonist pre-treatment) or subcutaneous OR-agonists (with or without sub-cutaneous OR-antagonist pre-
treatment). (Abbreviations: i.p.=intraperitoneal, OR=opioid receptor, OVA=ovalbumin, BW=body weight, {=sacrifice).
doi:10.1371/journal.pone.0039841.g005
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24 M). Displacement of radiolabled
ligands was measured by scintillation counts. The specific binding
was determined as the difference between total binding of the
radiolabeled ligands and nonspecific binding, determined in the
presence of an excess of unlabelled ligands. Results were displayed
in % dislocation of radiolabeled MOR-agonist ([
3H]DAMGO),
KOR-agonist ([
3H]U-69,593) or DOR-agonist ([
3H]DADLE).
Displacement of 25–50% was rated as moderate displacement and
51–100% as strong displacement.
Ex vivo re-stimulation of mesenteric lymph node
MLN isolated cells were re-stimulated ex vivo with OVA as
described previously [57]. Briefly, MLNs were homogenized with
a syringe plunger in a cell strainer (BD Falcon, Switzerland). Cells
were centrifuged and washed 26 in RPMI medium (Sigma)
complemented with 10% fetal bovine serum (FBS; Bioconcept,
France), 1% L-glutamine, 1% Penicillin/Streptomycin 0.1%
Gentamycin, 50 mM b-mercaptoethanol (all: Sigma-Aldrich,
Germany). Cells (3610
5 cells/well) were cultured in 96 well flat
bottom plate (Milian, Switzerland) in the absence or presence of
OVA (1 mg/ml). After 72 hrs of culture, plates (including
supernatant and cells) were frozen at 220uC.
Quantification of cytokines in cell culture supernatant
Mouse IL-4, IL-5, IL-10, and IFNc were measured using the
mouse Th-1/Th-2 4-plex multiplex kit (MesoScale DiscoveryH,
USA) according to the manufacturer’s instructions.
Quantification of total plasma IgE and OVA-specific IgE
by ELISA
Blood was collected in heparin tubes at sacrifice, centrifuged,
aliquoted, and stored at 220uC until use. Total IgE concentration
and mouse mast cell protease-1 (MMCP-1) were measured by
ELISA Kit (BD Bioscience, USA and Moredune Scientific, UK,
respectively) according to the manufacturer’s instructions. For
detection of OVA-specific IgE [58], 96 well plates were coated
with anti-mouse IgE antibody (BD Pharmingen, Switzerland) over
night. The next day plates were blocked with 1% bovine serum
albumin in phosphate buffered saline plus 0.5% Tween20 (Sigma
Aldrich, Germany) (PBSAT) for 1 h at 37uC, washed with PBSAT
and samples were added starting with a dilution serum to PBSAT
1:10 diluting sequentially 1:2. Mouse anti-OVA IgE (Serotec, UK)
served as standard with a starting concentration of 200 ng/ml.
Following incubation at 37uC for 2 h, plates were washed and
biotinylated OVA (see below) was added at a concentration of
4 mg/ml with a subsequent incubation for 1 h at 37uC. Before
development with 3,39,5,59 – tetramethylbenzidine (KPL, US)
plates were incubated for 30 min in the dark at 37uC with horse
radish peroxidase-conjugated streptavidine (KPL, US). Colorimet-
ric reaction was stopped with 1 N HCl.
The ODs of all ELISAs were read at 450 nm with a Dynex
MRX II (Dynex Technologies, Germany). For biotinylation, 2 ml
of OVA (10 mg/ml) and 1 mg of sulfo-LC-NHS-biotin (Molecular
Biosciences, US) were incubated on a rotating wheel for 1 h at
RT. The solution was then loaded on a PD-10 Sephadex G25M
column (Amersham Biosciences, Sweden) to remove excess biotin.
Protein concentration was determined using standard procedures
and biotinylation was verified by Western Blot analysis.
Mast cell quantification
For mast cell quantification in the small intestinal mucosa
0.5 cm of the proximal jejunum were rinsed with PBS, placed in
10% formalin (Sigma-Aldrich, Germany), and embedded in
paraffin using standard histological techniques. Slides (5 mm) were
cut and mucosal mast cells stained for chloroacetate esterase
activity [35] and tissue counter stained with haematoxylin. Mast
cell numbers were determined by counting chloroacetate-positive
cells under a light microscope (4006magnification). Mast cells in
at least 5 villi (OVA-challenged groups) or 10 villi (saline-
challenged groups) were counted and the results were expressed
in number of mast cells/villus.
Statistics
For each experiment a gate keeper strategy was used, that allowed
comparisons between treatment groups and OVA-challenged
positive controls only if the groups ‘‘saline’’ and ‘‘OVA’’ showed
significant differences. Results are expressed as median with
interquartile ranges. Clinical macroscopic scores at the 6
th challenge
comprisedclinicalandinsituobservations(scores1–5).Clinicalsumof
scores was calculated as sum of the clinical scores (scores 1–4) from all
6 challenges with a score of 0 assigned to the 1
st and 2
nd challenge
according to the progressive nature of the symptoms with multiple
challenges. Wilcoxon-Test was used to analyze differences between
groups. Tests were performed two-sided. P-values of less than 0.05
were considered significant. The software used for the calculations
was R 2.6.1 (http://www.r-project.org).
Supporting Information
Figure S1 KOR-agonist (U50’488) decreases total plas-
ma IgE in OVA-allergic mice. OVA-sensitized mice were
challenged with saline (Saline) or OVA (OVA) with or without
pre-treatment. The graph shows the concentration of plasma IgE
at sacrifice after subcutaneous treatment with 5 mg/kgBW KOR-
agonist U50’488 (U50’488), with 20 mg/kgBW NorBNI
(U50’488+NorBNI), or with NorBNI alone (NorBNI). Each dot
represents the corresponding value for one animal and the bars
represent the median and interquartile range, * p,0.05; n=5–10.
(TIF)
Table 2. In vitro opioid receptor-displacement assay.
Assay used Receptors/Cells used
Reference
compound Reference of assay
Radio- ligand
(concentration) Incubation
d2(h) (DOP) human recomb./CHO cells DPDPE Simonin et al. (1994) [
3H]DADLE (0.5 nM) 120 min/22uC
k (KOP) rat recomb./CHO cells U 50’488 Meng et al. (1993) [
3H]U 69’593 (1 nM) 60 min/22uC
m(h) (MOP) human recomb./HEK-293 cells DAMGO Wang et al. (1994) [
3H]DAMGO (0.5 nM) 120 min/22uC
(Abbr.: CHO=Chinese hamster Ovary, HEK=Human embryonic kidney, DOP=delta opioid; KOP=kappa opioid, MOP=mu opioid, recomb.=recombinant).
doi:10.1371/journal.pone.0039841.t002
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IL-10 in OVA-allergic mice. OVA-sensitized mice were
challenged with saline (Saline) or OVA (OVA) with or without
pre-treatment. Panels A and B show the concentration of IL-5 (A)
and IL-10 (B) in supernatant from ex vivo re-stimulated mesenteric
lymphocytes of mice subcutaneously treated with 5 mg/kgBW
MOR-agonist (DAMGO) and naloxone-methiodide (DAM-
GO+N-M 1 mg), or naloxone methiodide alone (N-M 1 mg).
Each dot represents the corresponding value for one animal and
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